Chronic Myeloid Leukemia Coverage from Every Angle
Advertisement
Advertisement

Accelerated-Phase CML: Is Dasatinib Plus Decitabine Active?

By: Jenna Carter, PhD
Posted: Friday, October 2, 2020

A recent article published in the American Journal of Hematology presented findings from a phase I/II study examining the efficacy and safety of combining the tyrosine kinase inhibitor dasatinib with the hypomethylating agent decitabine in treating patients with accelerated-phase chronic myeloid leukemia (CML). Jorge Cortes, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues, stated that traditional single-arm tyrosine kinase treatments often yielded short-lived, modest responses, especially in patients with advanced-phase CML.

A total of 30 patients were enrolled in the study, including patients with accelerated-phase CML (7), blast-phase CML (19), and Philadelphia chromosome–positive acute myeloid leukemia (4). Two different dose schedules were investigated, with the target dose set at 10 mg/m2 or 20 mg/m2 of decitabine daily for 10 days plus 140 mg of dasatinib daily.

A total of 13 patients achieved a major hematologic response, and 6 achieved a minor hematologic response. The median overall survival was 13.8 months, with significantly higher overall survival among patients who achieved a hematologic response compared with those who did not (not reached vs. 4.65 months; P < .001). Safety analyses revealed that 28 patients had adverse events greater than or equal to 3, but no dose-limiting toxicities at the starting doses of the schedules tested. Efficacy analyses with the novel combination therapy revealed that nearly half of treated patients achieved a major hematologic event, and there was no dose-limiting toxicity at the starting dose with either dosing schedule used.

Dr. Cortes and colleagues concluded: “Decitabine plus dasatinib is a safe and novel approach for managing patients with advanced CML, with a survival probability among responders that appears better than what would be expected with either agent alone.”

Disclosure: For full disclosure of the study authors, visit wiley.com.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.